TY - JOUR
T1 - Machine Learning Driven by Magnetic Resonance Imaging for the Classification of Alzheimer Disease Progression
T2 - Systematic Review and Meta-Analysis
AU - Battineni, Gopi
AU - Chintalapudi, Nalini
AU - Amenta, Francesco
N1 - Publisher Copyright:
© 2024 JMIR Publications Inc.. All rights reserved.
PY - 2024
Y1 - 2024
N2 - Background: To diagnose Alzheimer disease (AD), individuals are classified according to the severity of their cognitive impairment. There are currently no specific causes or conditions for this disease. Objective: The purpose of this systematic review and meta-analysis was to assess AD prevalence across different stages using machine learning (ML) approaches comprehensively. Methods: The selection of papers was conducted in 3 phases, as per PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) 2020 guidelines: identification, screening, and final inclusion. The final analysis included 24 papers that met the criteria. The selection of ML approaches for AD diagnosis was rigorously based on their relevance to the investigation. The prevalence of patients with AD at 2, 3, 4, and 6 stages was illustrated through the use of forest plots. Results: The prevalence rate for both cognitively normal (CN) and AD across 6 studies was 49.28% (95% CI 46.12%-52.45%; P=.32). The prevalence estimate for the 3 stages of cognitive impairment (CN, mild cognitive impairment, and AD) is 29.75% (95% CI 25.11%-34.84%, P<.001). Among 5 studies with 14,839 participants, the analysis of 4 stages (nondemented, moderately demented, mildly demented, and AD) found an overall prevalence of 13.13% (95% CI 3.75%-36.66%; P<.001). In addition, 4 studies involving 3819 participants estimated the prevalence of 6 stages (CN, significant memory concern, early mild cognitive impairment, mild cognitive impairment, late mild cognitive impairment, and AD), yielding a prevalence of 23.75% (95% CI 12.22%-41.12%; P<.001). Conclusions: The significant heterogeneity observed across studies reveals that demographic and setting characteristics are responsible for the impact on AD prevalence estimates. This study shows how ML approaches can be used to describe AD prevalence across different stages, which provides valuable insights for future research.
AB - Background: To diagnose Alzheimer disease (AD), individuals are classified according to the severity of their cognitive impairment. There are currently no specific causes or conditions for this disease. Objective: The purpose of this systematic review and meta-analysis was to assess AD prevalence across different stages using machine learning (ML) approaches comprehensively. Methods: The selection of papers was conducted in 3 phases, as per PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) 2020 guidelines: identification, screening, and final inclusion. The final analysis included 24 papers that met the criteria. The selection of ML approaches for AD diagnosis was rigorously based on their relevance to the investigation. The prevalence of patients with AD at 2, 3, 4, and 6 stages was illustrated through the use of forest plots. Results: The prevalence rate for both cognitively normal (CN) and AD across 6 studies was 49.28% (95% CI 46.12%-52.45%; P=.32). The prevalence estimate for the 3 stages of cognitive impairment (CN, mild cognitive impairment, and AD) is 29.75% (95% CI 25.11%-34.84%, P<.001). Among 5 studies with 14,839 participants, the analysis of 4 stages (nondemented, moderately demented, mildly demented, and AD) found an overall prevalence of 13.13% (95% CI 3.75%-36.66%; P<.001). In addition, 4 studies involving 3819 participants estimated the prevalence of 6 stages (CN, significant memory concern, early mild cognitive impairment, mild cognitive impairment, late mild cognitive impairment, and AD), yielding a prevalence of 23.75% (95% CI 12.22%-41.12%; P<.001). Conclusions: The significant heterogeneity observed across studies reveals that demographic and setting characteristics are responsible for the impact on AD prevalence estimates. This study shows how ML approaches can be used to describe AD prevalence across different stages, which provides valuable insights for future research.
KW - Alzheimer disease
KW - biomarkers
KW - classification
KW - cognitive impairment
KW - imaging modalities
KW - machine learning
KW - magnetic resonance imaging
KW - meta-analysis
KW - ML-based diagnosis
KW - MRI
KW - prevalence
KW - systematic review
UR - https://www.scopus.com/pages/publications/85214406326
U2 - 10.2196/59370
DO - 10.2196/59370
M3 - Review article
AN - SCOPUS:85214406326
SN - 2561-7605
VL - 7
JO - JMIR Aging
JF - JMIR Aging
M1 - e59370
ER -